Real Tech Fund Utilizes Japan's First AI / IoT Technology
Invested in "Neurospace Co., Ltd.", which develops a sleep analysis platform

Euglena Investment Co., Ltd.

　Euglena Investment Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative: Akihiko Nagata) is a new investment destination for the venture capital fund "Real Tech Fund", and is developing a sleep improvement program business for companies. We are pleased to inform you that we have invested in "Neurospace").

　In modern Japan, there are many business people who suffer from chronic sleep deprivation due to day-night reversal and long working hours, and the living environment where sleep is sacrificed is a health risk such as the onset of cancer and heart disease. Recent epidemiological studies have shown that it increases. Under such circumstances, an increasing number of companies are taking measures to eliminate sleep-related concerns of employees in terms of improving corporate productivity and health management.
　Neurospace is a sleep improvement program that applies cutting-edge sleep technology and clinical know-how developed in collaboration with medical institutions for companies working to improve employee sleep problems as part of their health management. It offers. In the future, Japan's first AI / IoT technology will be utilized by utilizing the big data accumulated through the provision of sleep improvement programs so far, and by independently developing sleep automatic analysis algorithms using AI and high-precision sleep measurement devices compatible with IoT. We aim to put into practical use a sleep analysis platform that utilizes.
　This time, the Real Tech Fund will underwrite the shares issued by Neurospace through a third-party allotment, and will support the acquisition of subsidies related to research and development and marketing activities.
　The details are as follows.

Investing in Neurospace Co., Ltd.

■ About the outline and support contents of Neurospace Co., Ltd.
　Date of establishment: December 17, 2013
　location　: 2-25 Kanda Sudacho, Chiyoda-ku, Tokyo GYB Akihabara 5F
　Representative　: Representative Director Takanori Kobayashi
　Capital　: 28.03 million yen (excluding capital reserve)
　Business: R & D related to sleep business and provision of related services
　HP　　: Https://neurospace.jp/
　 Support content: Support for R & D-related subsidies and marketing activities
　Investment period: August 2017

■ About Realtech Fund (HP: http://www.realtech.fund)
　Our 100% subsidiary of Euglena Investment, SMBC Nikko Securities, Ribanesu "Limited Liability Company was founded three companies Euglena in venture capital funds that SMBC Nikko Ribanesu capital" to management and operation, the investment development of the real tech venture as the main purpose is. With a total of 30 participating companies and a fund size of 9.4 billion yen (as of October 2017), it is one of the largest real tech-specialized funds in Japan. We are investing in and nurturing real tech ventures with the following operating companies that are investors.

Investors: Euglena Investment Co., Ltd., SMBC Nikko Securities Co., Ltd., Leave a Nest Co., Ltd., Japan Tobacco Inc., Mitsui Fudosan Co., Ltd.,
　　　　　Yoshinoya Holdings Co., Ltd., Rohto Pharmaceutical Co., Ltd., Kanetsu Co., Ltd., Dentsu Inc., Tokyo Century Co., Ltd., Kyowa Hakko,
　　　　　Kirin Co., Ltd., Aizawa Securities Co., Ltd., Shimizu Corporation, Sumitomo Mitsui Banking Corporation, ANA Holdings Co., Ltd., THK Co., Ltd.,
　　　　　Toyo Aluminum Co., Ltd., Dai-ichi Life Insurance Co., Ltd., CQ Ventures Co., Ltd., East Japan Railway Company, Nihon Unisys, Ltd.,
　　　　　JCU Co., Ltd., Toyobo Co., Ltd., SoftBank Corp., Mitsubishi Electric Corporation, AS ONE Corporation, ShinMaywa Industry Co., Ltd., Mitsubishi Corporation,
　　　　　Mitsui Chemicals Ltd., Isuzu Motors Ltd. (30 companies in total, as of October 2017)

​ ​

-Contact for inquiries from the press-
Euglena Co., Ltd. Corporate Communication Division